stockrow
Friday 6 November 2026
Export ALUR’s income statement to Excel — free account
Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024.
- Revenue
- −47.2%
- EPS
- −46.5%
- Free cash flow
- +66.0%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow ALUR
Alert me
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.72 | 0.61 | 0.93 | 0.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.80) | (1.75) | (2.43) | (2.33) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.97 | 4.93 | 4.71 | 3.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.31) | (2.59) | (2.19) | (1.74) | |
EV/FCF |
(3.22) | (2.54) | (2.16) | (1.71) | |
Quick Ratio |
0.23 | 0.24 | 0.87 | 1.60 | |
Current Ratio |
0.30 | 0.33 | 1.26 | 2.02 | |
Net Debt/EBITDA |
1.42 | 0.88 | (2.79) | (2.43) | |
Debt/Assets |
0.00% | 0.00% | 177.72% | 102.13% | |
Debt/Equity |
0.00 | 0.00 | (0.39) | (0.45) | |
Asset Turnover |
0.48 | 0.63 | 0.50 | 0.53 | |
Operating CF/Net income |
0.53 | 0.88 | 0.55 | 0.82 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
30.95% | 31.30% | 75.85% | 53.27% | |
Selling, General and Administrative Expense of Revenue |
137.36% | 187.41% | 335.52% | 226.37% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
21.65% | 19.43% | 19.98% | 30.07% | |
Graham Net Nets |
(8.94) | (8.63) | (5.43) | (3.87) | |
Graham Number |
337.27 | 438.01 | 607.19 | 289.10 | |
Earnings Yield |
(570.44%) | (301.34%) | (332.72%) | (77.56%) | |
Free Cash Flow Yield |
(258.39%) | (318.30%) | (235.59%) | (239.08%) | |
Revenue per Share |
3.31 | 7.18 | 5.13 | 6.94 | |
Operating CF per Share |
(3.62) | (10.57) | (12.64) | (15.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.62) | (10.57) | (12.64) | (15.64) | |
Cash per Share |
5.68 | 10.75 | 11.85 | 26.13 | |
Shareholders Equity per Share |
(87.49) | (153.37) | (160.15) | (131.39) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(87.49) | (153.37) | (160.15) | (131.39) | |
Free Cash Flow |
(3.22) | (5.32) | (6.54) | (7.61) | |
Working Capital |
(25.95) | (25.65) | 2.98 | 11.87 | |
Net Current Asset Value |
(80.60) | (80.17) | (86.47) | (68.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.89 | 5.54 | 6.96 | 9.60 | |
Average Payables |
4.02 | 5.07 | 6.60 | 5.91 | |
Average Inventory |
2.71 | 3.04 | 4.12 | 4.28 | |
Average Assets |
26.20 | 24.29 | 34.42 | 37.36 | |
Average Common Equity |
(73.85) | (77.58) | (73.86) | (67.28) |
Columns are period end dates · fundamentals updated 26 Oct 2026